{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:28:16Z","timestamp":1792859296387,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01500-9","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T23:09:42Z","timestamp":1736464182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stage-specific efficacy of osimertinib in treatment-na\u00efve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-3683","authenticated-orcid":false,"given":"Yoshihiko","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Isa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Mizumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Nakatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Kuwako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"1500_CR1","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7:78985\u201378993. https:\/\/doi.org\/10.18632\/oncotarget.12587","journal-title":"Oncotarget"},{"key":"1500_CR2","doi-asserted-by":"publisher","unstructured":"Greenhalgh J, Boland A, Bates V et al First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation-positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 2021:CD010383. https:\/\/doi.org\/10.1002\/14651858.CD010383.pub3","DOI":"10.1002\/14651858.CD010383.pub3"},{"key":"1500_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"key":"1500_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"1500_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"1500_CR6","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa K, Garon EB, Seto T et al (2019) Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:1655\u20131669. https:\/\/doi.org\/10.1016\/S1470-2045(19)30634-5","journal-title":"Lancet Oncol"},{"key":"1500_CR7","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y et al (2023) Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 389:1935\u20131948. https:\/\/doi.org\/10.1056\/NEJMoa2306434","journal-title":"N Engl J Med"},{"key":"1500_CR8","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E et al (2024) Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med 391:1486\u20131498. https:\/\/doi.org\/10.1056\/NEJMoa2403614","journal-title":"N Engl J Med"},{"key":"1500_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jtho.2023.10.001","volume":"19","author":"P Stockhammer","year":"2024","unstructured":"Stockhammer P, Grant M, Wurtz A et al (2024) Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. J Thorac Oncol 19:240\u2013251. https:\/\/doi.org\/10.1016\/j.jtho.2023.10.001","journal-title":"J Thorac Oncol"},{"key":"1500_CR10","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00432-019-03001-2","volume":"145","author":"LL Deng","year":"2019","unstructured":"Deng LL, Gao G, Deng HB, Wang F et al (2019) Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC. J Cancer Res Clin Oncol 145:2613\u20132624. https:\/\/doi.org\/10.1007\/s00432-019-03001-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"1500_CR11","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ng.3990","volume":"49","author":"CM Blakely","year":"2017","unstructured":"Blakely CM, Watkins TBK, Wu W et al (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693\u20131704. https:\/\/doi.org\/10.1038\/ng.3990","journal-title":"Nat Genet"},{"key":"1500_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","volume":"20","author":"K Qin","year":"2020","unstructured":"Qin K, Hou H, Liang Y, Zhang X (2020) Prognostic value of TP53 concurrent mutations for EGFR and ALK-TKI-based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. BMC Cancer 20:328. https:\/\/doi.org\/10.1186\/s12885-020-06805-5","journal-title":"BMC Cancer"},{"key":"1500_CR13","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1200\/JCO.2015.64.2322","volume":"34","author":"T Kawaguchi","year":"2016","unstructured":"Kawaguchi T, Koh Y, Ando M et al (2016) Prospective analysis of oncogenic driver mutations and environmental factors: Japan molecular epidemiology for lung cancer study. J Clin Oncol 34:2247\u20132257. https:\/\/doi.org\/10.1200\/JCO.2015.64.2322","journal-title":"J Clin Oncol"},{"key":"1500_CR14","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1016\/j.cllc.2020.05.023","volume":"22","author":"A Tamiya","year":"2021","unstructured":"Tamiya A, Isa SI, Taniguchi Y et al (2021) Prospective observational study of treatment resistance-related gene screening using plasma circulating tumor DNA in third-generation EGFR-TKI osimertinib therapy (elucidator). Clin Lung Cancer 22:e336\u2013e341. https:\/\/doi.org\/10.1016\/j.cllc.2020.05.023","journal-title":"Clin Lung Cancer"},{"key":"1500_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11:39\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2015.09.009","journal-title":"J Thorac Oncol"},{"key":"1500_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/OTT.S407301","volume":"16","author":"KC Chen","year":"2023","unstructured":"Chen KC, Huang YH, Hsu KH, Tseng JS, Chang GC, Yang TY (2023) The role of neutrophil-to-lymphocyte ratio in advanced EGFR-mutant NSCLC patients treated with first-line osimertinib. Onco Targets Ther 16:317\u2013326. https:\/\/doi.org\/10.2147\/OTT.S407301","journal-title":"Onco Targets Ther"},{"key":"1500_CR17","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1111\/1759-7714.14608","volume":"13","author":"S Teranishi","year":"2022","unstructured":"Teranishi S, Sugimoto C, Nagaoka S et al (2022) Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib. Thorac Cancer 13:2741\u20132750. https:\/\/doi.org\/10.1111\/1759-7714.14608","journal-title":"Thorac Cancer"},{"key":"1500_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/fon-2021-0947","volume":"18","author":"S Takamizawa","year":"2022","unstructured":"Takamizawa S, Okuma Y, Kato Y, Hakozaki T, Kitagawa S, Zenke Y (2022) First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. Future Oncol 18:291\u2013300. https:\/\/doi.org\/10.2217\/fon-2021-0947","journal-title":"Future Oncol"},{"key":"1500_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10637-021-01195-2","volume":"40","author":"S Igawa","year":"2022","unstructured":"Igawa S, Fukui T, Kasajima M et al (2022) First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: a prospective observational study. Invest New Drugs 40:430\u2013437. https:\/\/doi.org\/10.1007\/s10637-021-01195-2","journal-title":"Invest New Drugs"},{"key":"1500_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12890-024-03212-5","volume":"24","author":"Y Taniguchi","year":"2024","unstructured":"Taniguchi Y, Tamiya A, Osuga M et al (2024) Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naive EGFR-mutated NSCLC based on performance status. BMC Pulm Med 24:407. https:\/\/doi.org\/10.1186\/s12890-024-03212-5","journal-title":"BMC Pulm Med"},{"key":"1500_CR21","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.resinv.2024.09.001","volume":"62","author":"M Anai","year":"2024","unstructured":"Anai M, Inoue H, Saruwatari K et al (2024) Negative-predictive value of SUVmax for evaluating the efficacy of osimertinib in EGFR mutation-positive non-small cell lung cancer. Respir Investig 62:1072\u20131078. https:\/\/doi.org\/10.1016\/j.resinv.2024.09.001","journal-title":"Respir Investig"},{"key":"1500_CR22","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.21037\/tlcr-21-461","volume":"10","author":"A Yoshimura","year":"2021","unstructured":"Yoshimura A, Yamada T, Okuma Y et al (2021) Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. Transl Lung Cancer Res 10:3582\u20133593. https:\/\/doi.org\/10.21037\/tlcr-21-461","journal-title":"Transl Lung Cancer Res"},{"key":"1500_CR23","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","volume":"24","author":"HA Yu","year":"2018","unstructured":"Yu HA, Suzawa K, Jordan E et al (2018) Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res 24:3108\u20133118. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2961","journal-title":"Clin Cancer Res"},{"key":"1500_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cllc.2023.02.010","volume":"24","author":"M Nishio","year":"2023","unstructured":"Nishio M, Paz-Ares L, Reck M et al (2023) RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and clinical outcome. Clin Lung Cancer 24:415\u2013428. https:\/\/doi.org\/10.1016\/j.cllc.2023.02.010","journal-title":"Clin Lung Cancer"},{"key":"1500_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4143\/crt.2023.728","volume":"56","author":"JS Lee","year":"2024","unstructured":"Lee JS, Kim EK, Kim KA, Shim HS (2024) Clinical impact of genomic and pathway alterations in stage I EGFR-mutant lung adenocarcinoma. Cancer Res Treat 56:104\u2013114. https:\/\/doi.org\/10.4143\/crt.2023.728","journal-title":"Cancer Res Treat"},{"key":"1500_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tlcr-21-754","volume":"11","author":"J Roeper","year":"2022","unstructured":"Roeper J, Christopoulos P, Falk M et al (2022) TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR-mutated non-small cell lung cancer IV patients treated with osimertinib. Transl Lung Cancer Res 11:4\u201313. https:\/\/doi.org\/10.21037\/tlcr-21-754","journal-title":"Transl Lung Cancer Res"},{"key":"1500_CR27","doi-asserted-by":"publisher","first-page":"107917","DOI":"10.1016\/j.lungcan.2024.107917","volume":"195","author":"A Tamiya","year":"2024","unstructured":"Tamiya A, Osuga M, Harada D et al (2024) Mechanisms of resistance and correlation between pretreatment co-alterations and p-prognosis to osimertinib in chemo-na\u00efve advanced non-small cell lung cancer. Lung Cancer 195:107917. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107917","journal-title":"Lung Cancer"},{"key":"1500_CR28","doi-asserted-by":"publisher","first-page":"101580","DOI":"10.1016\/j.esmoop.2023.101580","volume":"8","author":"EB Garon","year":"2023","unstructured":"Garon EB, Reck M, Nishio K et al (2023) Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open 8:101580. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101580","journal-title":"ESMO Open"},{"issue":"Supplement 1","key":"1500_CR29","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29(Supplement 1):i10\u2013i19. https:\/\/doi.org\/10.1093\/annonc\/mdx703","journal-title":"Ann Oncol"},{"key":"1500_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M (2019) Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 121:725\u2013737. https:\/\/doi.org\/10.1038\/s41416-019-0573-8","journal-title":"Br J Cancer"},{"key":"1500_CR31","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.1200\/JCO.2005.01.0793","volume":"23","author":"T Takano","year":"2005","unstructured":"Takano T, Ohe Y, Sakamoto H et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol 23:6829\u20136837. https:\/\/doi.org\/10.1200\/JCO.2005.01.0793","journal-title":"J Clin Oncol"},{"key":"1500_CR32","doi-asserted-by":"publisher","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","volume":"23","author":"DW Bell","year":"2005","unstructured":"Bell DW, Lynch TJ, Haserlat SM et al (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials. J Clin Oncol 23:8081\u20138092. https:\/\/doi.org\/10.1200\/JCO.2005.02.7078","journal-title":"J Clin Oncol"},{"key":"1500_CR33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1200\/JCO.2009.24.3030","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Shepherd FA, Hirsh V et al (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28:744\u2013752. https:\/\/doi.org\/10.1200\/JCO.2009.24.3030","journal-title":"J Clin Oncol"},{"key":"1500_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.lungcan.2012.11.009","volume":"79","author":"TJ Grob","year":"2013","unstructured":"Grob TJ, Hoenig T, Clauditz TS et al (2013) Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer 79:221\u2013227. https:\/\/doi.org\/10.1016\/j.lungcan.2012.11.009","journal-title":"Lung Cancer"},{"key":"1500_CR35","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","volume":"29","author":"M Fukuoka","year":"2011","unstructured":"Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866\u20132874. https:\/\/doi.org\/10.1200\/JCO.2010.33.4235","journal-title":"J Clin Oncol"},{"key":"1500_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.lungcan.2015.06.008","volume":"89","author":"L Shan","year":"2015","unstructured":"Shan L, Wang Z, Guo L et al (2015) Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer 89:337\u2013342. https:\/\/doi.org\/10.1016\/j.lungcan.2015.06.008","journal-title":"Lung Cancer"},{"key":"1500_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s11523-018-0594-x","volume":"13","author":"A Ruiz-Pati\u00f1o","year":"2018","unstructured":"Ruiz-Pati\u00f1o A, Castro CD, Ricaurte LM et al (2018) EGFR amplification and sensitizing mutations correlate with survival in lung adenocarcinoma patients treated with erlotinib (MutP-CLICaP). Target Oncol 13:621\u2013629. https:\/\/doi.org\/10.1007\/s11523-018-0594-x","journal-title":"Target Oncol"},{"key":"1500_CR38","doi-asserted-by":"publisher","first-page":"11006","DOI":"10.4238\/2015.September.21.13","volume":"14","author":"XF Jia","year":"2015","unstructured":"Jia XF, Li J, Zhao HB, Liu J, Liu JJ (2015) Correlation of EGFR gene amplification with invasion and metastasis of non-small cell lung cancer. Genet Mol Res 14:11006\u201311012. https:\/\/doi.org\/10.4238\/2015.September.21.13","journal-title":"Genet Mol Res"},{"key":"1500_CR39","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1158\/1078-0432.CCR-14-0450","volume":"21","author":"HU Schildhaus","year":"2015","unstructured":"Schildhaus HU, Schultheis AM, R\u00fcschoff J et al (2015) MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res 21:907\u2013915. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0450","journal-title":"Clin Cancer Res"},{"key":"1500_CR40","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.18.00177","volume":"37","author":"GGY Lai","year":"2019","unstructured":"Lai GGY, Lim TH, Lim J et al (2019) Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol 37:876\u2013884. https:\/\/doi.org\/10.1200\/JCO.18.00177","journal-title":"J Clin Oncol"},{"key":"1500_CR41","doi-asserted-by":"publisher","first-page":"e870","DOI":"10.1016\/j.cllc.2021.05.002","volume":"22","author":"MS Clement","year":"2021","unstructured":"Clement MS, Ebert EBF, Meldgaard P, Sorensen BS (2021) Co-occurring MET amplification predicts inferior clinical response to first-line erlotinib in advanced stage EGFR-mutated NSCLC patients. Clin Lung Cancer 22:e870\u2013e877. https:\/\/doi.org\/10.1016\/j.cllc.2021.05.002","journal-title":"Clin Lung Cancer"},{"key":"1500_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11523-022-00915-9","volume":"17","author":"A Akli","year":"2022","unstructured":"Akli A, Girard N, Fallet V et al (2022) Histomolecular resistance mechanisms to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer: a multicentric retrospective French study. Target Oncol 17:675\u2013682. https:\/\/doi.org\/10.1007\/s11523-022-00915-9","journal-title":"Target Oncol"},{"key":"1500_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","volume":"137","author":"C Mehlman","year":"2019","unstructured":"Mehlman C, Cadranel J, Rousseau-Bussac G et al (2019) Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer 137:149\u2013156. https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.019","journal-title":"Lung Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01500-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01500-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01500-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:03:12Z","timestamp":1736467392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01500-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":43,"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01500-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective observational study was registered on December 10, 2018, in the Japanese Register of Clinical Trials (JRCT; Clinical Trial Number: jRCTs031180051). Written informed consent was obtained from all patients before the study began, and the National Hospital Organization Review Board for Clinical Trials approved this protocol prior to the start of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Taniguchi Y has received honoraria from Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca, and MSD. Tamiya A received honoraria from Eli Lilly, Ono Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Amgen, Taiho Pharmaceutical, Kyowa-Kirin, MSD, Takeda Pharmaceutical, Nihon-Kayaku, Novartis, Thermo Fischer, Amgen, Tsumura, Daiich-Sankyo, and Merck BioFarma, and research funding from Daiichi-Sankyo, Beigene, and AstraZeneca. Oki M has received Honoraria from AMCO, AstraZeneca, Canon Medical Systems, Chugai Pharmaceutical, Fujifilm Toyama Chemical, Kaneka Medix, Merit Medical Japan, Novartis Pharma, Olympus and Sanofi, and research funding from AbbVie, AstraZeneca, Chugai Pharmaceutical, Fujifilm Toyama Chemical, GlaxoSmithKline, Janssen Pharmaceutical, MSD, Ono Pharmaceutical, Parxel International, Pfizer, Sanofi. Mori M received honoraria from AstraZeneca, Boehringer Ingelheim, MSD, Eli Lilly, Novartis, Chugai Pharmaceutical, Taiho Pharmaceutical, Kyowa-kirin, Ono Pharmaceutical, Otsuka, Nihon-kayaku, Pfizer, Daiici-Sankyo, Takeda Pharmaceutical, and Shionogi and research funding from Chugai Pharmaceutical, Ono Pharmaceutical, MSD, and Delt-fly. Koh Y has received honoraria from Chugai Pharmaceutical, Guardant Health, Amgen, Takeda Pharmaceutical, and Tosoh Corporation and has received consulting or advisory roles from Tosoh Corporation and research funding from Boehringer Ingelheim, AstraZeneca, Chugai Pharmaceutical, Tosoh Corporation, Daiichi Sankyo, Zeon Corporation, Amgen, and Takeda Pharmaceutical. The other co-authors received no honoraria or research funding.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}